Skip to main
SIBN

SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE Inc (SIBN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

SI-BONE is well-positioned for growth in the medical device industry, with strong financials and a positive market outlook. With a new partnership and product launches in the pipeline, the company's potential for revenue growth is promising, leading analysts to maintain a Buy recommendation and a target price of $24. However, competition and possible changes in reimbursement pose as potential risks for the company's future performance.

Bears say

SI-BONE is a company with potential for growth in the medical device market due to its unique and effective products, as evidenced by their higher than expected revenue and active physician numbers. However, there are headwinds in the short term such as weather disruptions and the onboarding of a new distributor, which may impact revenue and profitability. The company has a strategic partnership with Smith & Nephew for its trauma and spine product portfolio, which could drive further growth, but the impact may not be fully realized in the current guidance. The company has shown strong financial performance and is expected to generate positive EBITDA in 2026, but there is limited visibility into the full potential impact of the partnership at this time.

SI-BONE Inc (SIBN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SI-BONE Inc (SIBN) Forecast

Analysts have given SI-BONE Inc (SIBN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, SI-BONE Inc (SIBN) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SI-BONE Inc (SIBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.